Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C

G. Firneisz, P. Lakatos, M. Horányi, A. Pár, Á Gógl, M. Abonyi, K. Dávid, J. Fehér, J. Gervain, E. Nemesánszky, Gy Tolvaj, G. Horváth, L. Telegdy, A. Csepregi, P. Ribiczey, B. Büki, E. Ibrányi, Zs Ozsvár, L. Pete, L. RókuszH. Osztrogonác, F. Szalay

Research output: Article

29 Citations (Scopus)

Abstract

Background: DPP IV is a cell surface ectoenzyme widely distributed in the human body. It has been implicated in T-cell activation, hepatocyte-extracellular-matrix interactions and fibroblast proliferation. Furthermore, upregulated CD26 expression has been found on the surface of human hepatoma cells transfected with hepatitis C virus (HCV) c-DNA. We examined the serum DPP IV activity in a large number of patients with chronic HCV infection in a cross-sectional study. We also investigated whether the activity differs from that in controls and depends upon the response to interferon (IFN) therapy. Methods: Serum DPP IV activity was measured by microplate-based (Multiskan-Plus-MKII, Labsystem) kinetic assay in 144 patients with chronic HCV infection. Seventy-four out of 144 patients (46 non-responders, 28 responders) were formerly treated with interferon. Sixty healthy blood donors served as controls. Gly-Pro-PNA (Bachem, Torrance, USA) was used as substrate. Results are expressed in nmol/ml/min (U/l). Shapiro-Wilk's test, Mann-Whitney U test and Spearman rank order correlation were used for statistical analysis. Results: Serum DPP IV activity was significantly higher (mean = 20.89 [s 9.6]) in patients with chronic HCV infection than in healthy controls (12.39 [2.76, P <10-5]). The enzyme activities significantly differed in naive HCV-positive patients (22.2 [9.89, P <10-5]) and non-responders (23.28 [9.57, P <10-5]) from that in the healthy controls and also from that in responders (13.69 [4.21]). Correlation was found between DPP IV activity and AST (r = 0.44, P <10-5), ALT (r = 0.44, P <10-5), GGT (r = 0.41, P <10-5) levels. Conclusion: Serum DPP IV activity seems to be an indicator of HCV induced liver injury. The activity may reflect the efficacy of interferon therapy.

Original languageEnglish
Pages (from-to)877-880
Number of pages4
JournalScandinavian Journal of Gastroenterology
Volume36
Issue number8
Publication statusPublished - 2001

Fingerprint

Dipeptidyl Peptidase 4
Chronic Hepatitis C
Hepacivirus
Virus Diseases
Serum
Interferons
glycylproline
Nonparametric Statistics
Blood Donors
Human Body
Extracellular Matrix
Hepatocytes
Hepatocellular Carcinoma
Fibroblasts
Cross-Sectional Studies
T-Lymphocytes
Liver
DNA
Wounds and Injuries
Enzymes

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. / Firneisz, G.; Lakatos, P.; Horányi, M.; Pár, A.; Gógl, Á; Abonyi, M.; Dávid, K.; Fehér, J.; Gervain, J.; Nemesánszky, E.; Tolvaj, Gy; Horváth, G.; Telegdy, L.; Csepregi, A.; Ribiczey, P.; Büki, B.; Ibrányi, E.; Ozsvár, Zs; Pete, L.; Rókusz, L.; Osztrogonác, H.; Szalay, F.

In: Scandinavian Journal of Gastroenterology, Vol. 36, No. 8, 2001, p. 877-880.

Research output: Article

Firneisz, G, Lakatos, P, Horányi, M, Pár, A, Gógl, Á, Abonyi, M, Dávid, K, Fehér, J, Gervain, J, Nemesánszky, E, Tolvaj, G, Horváth, G, Telegdy, L, Csepregi, A, Ribiczey, P, Büki, B, Ibrányi, E, Ozsvár, Z, Pete, L, Rókusz, L, Osztrogonác, H & Szalay, F 2001, 'Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C', Scandinavian Journal of Gastroenterology, vol. 36, no. 8, pp. 877-880.
Firneisz, G. ; Lakatos, P. ; Horányi, M. ; Pár, A. ; Gógl, Á ; Abonyi, M. ; Dávid, K. ; Fehér, J. ; Gervain, J. ; Nemesánszky, E. ; Tolvaj, Gy ; Horváth, G. ; Telegdy, L. ; Csepregi, A. ; Ribiczey, P. ; Büki, B. ; Ibrányi, E. ; Ozsvár, Zs ; Pete, L. ; Rókusz, L. ; Osztrogonác, H. ; Szalay, F. / Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. In: Scandinavian Journal of Gastroenterology. 2001 ; Vol. 36, No. 8. pp. 877-880.
@article{a28a932cf1844568b258ce118e33f9b2,
title = "Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C",
abstract = "Background: DPP IV is a cell surface ectoenzyme widely distributed in the human body. It has been implicated in T-cell activation, hepatocyte-extracellular-matrix interactions and fibroblast proliferation. Furthermore, upregulated CD26 expression has been found on the surface of human hepatoma cells transfected with hepatitis C virus (HCV) c-DNA. We examined the serum DPP IV activity in a large number of patients with chronic HCV infection in a cross-sectional study. We also investigated whether the activity differs from that in controls and depends upon the response to interferon (IFN) therapy. Methods: Serum DPP IV activity was measured by microplate-based (Multiskan-Plus-MKII, Labsystem) kinetic assay in 144 patients with chronic HCV infection. Seventy-four out of 144 patients (46 non-responders, 28 responders) were formerly treated with interferon. Sixty healthy blood donors served as controls. Gly-Pro-PNA (Bachem, Torrance, USA) was used as substrate. Results are expressed in nmol/ml/min (U/l). Shapiro-Wilk's test, Mann-Whitney U test and Spearman rank order correlation were used for statistical analysis. Results: Serum DPP IV activity was significantly higher (mean = 20.89 [s 9.6]) in patients with chronic HCV infection than in healthy controls (12.39 [2.76, P <10-5]). The enzyme activities significantly differed in naive HCV-positive patients (22.2 [9.89, P <10-5]) and non-responders (23.28 [9.57, P <10-5]) from that in the healthy controls and also from that in responders (13.69 [4.21]). Correlation was found between DPP IV activity and AST (r = 0.44, P <10-5), ALT (r = 0.44, P <10-5), GGT (r = 0.41, P <10-5) levels. Conclusion: Serum DPP IV activity seems to be an indicator of HCV induced liver injury. The activity may reflect the efficacy of interferon therapy.",
keywords = "CD26, Dipeptidyl peptidase IV, DPP IV, HCV, Hepatitis, Interferon",
author = "G. Firneisz and P. Lakatos and M. Hor{\'a}nyi and A. P{\'a}r and {\'A} G{\'o}gl and M. Abonyi and K. D{\'a}vid and J. Feh{\'e}r and J. Gervain and E. Nemes{\'a}nszky and Gy Tolvaj and G. Horv{\'a}th and L. Telegdy and A. Csepregi and P. Ribiczey and B. B{\"u}ki and E. Ibr{\'a}nyi and Zs Ozsv{\'a}r and L. Pete and L. R{\'o}kusz and H. Osztrogon{\'a}c and F. Szalay",
year = "2001",
language = "English",
volume = "36",
pages = "877--880",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C

AU - Firneisz, G.

AU - Lakatos, P.

AU - Horányi, M.

AU - Pár, A.

AU - Gógl, Á

AU - Abonyi, M.

AU - Dávid, K.

AU - Fehér, J.

AU - Gervain, J.

AU - Nemesánszky, E.

AU - Tolvaj, Gy

AU - Horváth, G.

AU - Telegdy, L.

AU - Csepregi, A.

AU - Ribiczey, P.

AU - Büki, B.

AU - Ibrányi, E.

AU - Ozsvár, Zs

AU - Pete, L.

AU - Rókusz, L.

AU - Osztrogonác, H.

AU - Szalay, F.

PY - 2001

Y1 - 2001

N2 - Background: DPP IV is a cell surface ectoenzyme widely distributed in the human body. It has been implicated in T-cell activation, hepatocyte-extracellular-matrix interactions and fibroblast proliferation. Furthermore, upregulated CD26 expression has been found on the surface of human hepatoma cells transfected with hepatitis C virus (HCV) c-DNA. We examined the serum DPP IV activity in a large number of patients with chronic HCV infection in a cross-sectional study. We also investigated whether the activity differs from that in controls and depends upon the response to interferon (IFN) therapy. Methods: Serum DPP IV activity was measured by microplate-based (Multiskan-Plus-MKII, Labsystem) kinetic assay in 144 patients with chronic HCV infection. Seventy-four out of 144 patients (46 non-responders, 28 responders) were formerly treated with interferon. Sixty healthy blood donors served as controls. Gly-Pro-PNA (Bachem, Torrance, USA) was used as substrate. Results are expressed in nmol/ml/min (U/l). Shapiro-Wilk's test, Mann-Whitney U test and Spearman rank order correlation were used for statistical analysis. Results: Serum DPP IV activity was significantly higher (mean = 20.89 [s 9.6]) in patients with chronic HCV infection than in healthy controls (12.39 [2.76, P <10-5]). The enzyme activities significantly differed in naive HCV-positive patients (22.2 [9.89, P <10-5]) and non-responders (23.28 [9.57, P <10-5]) from that in the healthy controls and also from that in responders (13.69 [4.21]). Correlation was found between DPP IV activity and AST (r = 0.44, P <10-5), ALT (r = 0.44, P <10-5), GGT (r = 0.41, P <10-5) levels. Conclusion: Serum DPP IV activity seems to be an indicator of HCV induced liver injury. The activity may reflect the efficacy of interferon therapy.

AB - Background: DPP IV is a cell surface ectoenzyme widely distributed in the human body. It has been implicated in T-cell activation, hepatocyte-extracellular-matrix interactions and fibroblast proliferation. Furthermore, upregulated CD26 expression has been found on the surface of human hepatoma cells transfected with hepatitis C virus (HCV) c-DNA. We examined the serum DPP IV activity in a large number of patients with chronic HCV infection in a cross-sectional study. We also investigated whether the activity differs from that in controls and depends upon the response to interferon (IFN) therapy. Methods: Serum DPP IV activity was measured by microplate-based (Multiskan-Plus-MKII, Labsystem) kinetic assay in 144 patients with chronic HCV infection. Seventy-four out of 144 patients (46 non-responders, 28 responders) were formerly treated with interferon. Sixty healthy blood donors served as controls. Gly-Pro-PNA (Bachem, Torrance, USA) was used as substrate. Results are expressed in nmol/ml/min (U/l). Shapiro-Wilk's test, Mann-Whitney U test and Spearman rank order correlation were used for statistical analysis. Results: Serum DPP IV activity was significantly higher (mean = 20.89 [s 9.6]) in patients with chronic HCV infection than in healthy controls (12.39 [2.76, P <10-5]). The enzyme activities significantly differed in naive HCV-positive patients (22.2 [9.89, P <10-5]) and non-responders (23.28 [9.57, P <10-5]) from that in the healthy controls and also from that in responders (13.69 [4.21]). Correlation was found between DPP IV activity and AST (r = 0.44, P <10-5), ALT (r = 0.44, P <10-5), GGT (r = 0.41, P <10-5) levels. Conclusion: Serum DPP IV activity seems to be an indicator of HCV induced liver injury. The activity may reflect the efficacy of interferon therapy.

KW - CD26

KW - Dipeptidyl peptidase IV

KW - DPP IV

KW - HCV

KW - Hepatitis

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=0034948257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034948257&partnerID=8YFLogxK

M3 - Article

C2 - 11495085

AN - SCOPUS:0034948257

VL - 36

SP - 877

EP - 880

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 8

ER -